CClinicalTrials.gg
CompletedNCT03348293Updated Aug 3, 2025

Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction

A Phase 1 interventional study of 3D printing in Breast Reconstruction and Breast Cancer, sponsored by Xijing Hospital. Completed at 1 site in China. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Xijing Hospital · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, the investigators created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection. Safety indicator, cosmetic outcome and autologous compatibility were evaluated.

Read the detailed description

3D image reconstruction and printing Magnetic model images data were firstly produced by Siemens Trio Tim 3. 0 T MRI. The relative scanning parameters were adjusted as follows: layer thickness 0.9mm; pixel pitch 0.625 mm. In general, the thicker the layer thickness and pixel pitch, the better resolution and the more similar reconstructed model the investigators will get. The MRI data were then imported into Mimics 17.0® [Materialise, Leuven, Belgium] for 3D reconstruction of the targeted area. In this software, the investigators can adjust threshold value to acclimatize to segment tumor area. After that, 3D models were calculated and output as .stl files. According to the requirements of surgical planning, the scope of tumor resection was created after 2 cm expansion of the tumor area, that is, the filling scope of the implant. Next, the investigators designed the personalized porous degradable scaffold. In order to guarantee no significant differences and deformation of the implanted scaffold, the investigators used the contour of tumor resection as the boundary of the scaffold, with flexible porous structure as the units of the scaffold. Boolean operation can help to achieve this target. Finally, the printing of the personalized porous biodegradable scaffold was carried out. Biologically active material PCL was selected and the deformation and degradation time were set for 2 years by adjusting the molecular weight of PCL. Theoretically, PCL with the molecular weight above 65,000 can stably exist for 2 years in vivo, and then it will gradually degrade into H2O and CO2.The PCL material was put into the 3D printer, which was developed by the State key laboratory for mechanical manufacturing systems engineering of Xi'an Jiaotong university. The personalized porous biodegradable scaffold was completed after printing and removing supports.

Procedure In this study,the investigators produced the bio-implant at least 10 days before surgery. Before surgery, the printed bio-implant has been prepared and obtained full sterilization. Simply, under general anaesthesia, lumpectomy and sentinel-lymph-node biopsy was performed firstly, followed by 3D-printing scaffold transplantation.

02

Conditions studied

  • Breast Reconstruction
  • Breast Cancer

Browse trials for

Keywords

  • biodegradable scaffold
  • immediate breast reconstruction
  • 3D printing
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Breast cancer patients
  • Tumor sized 3 cm to 6 cm
  • ECOG score 1-2
  • Multiple diffuse lesions in one quadrant
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Triple negative breast cancer patients
  • Participant in another clinical study
  • Pregnancy and breastfeeding
  • Patients with nipple infringement
  • Inflammatory breast carcinoma
  • Paget's disease
  • Serious operative contraindication
  • Contraindication for MRI
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    3D printing patient

    Immediate breast reconstruction using 3D printing personalized scaffold

    Procedure: 3D printing

Interventions

  • Procedure3D printing

    Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.

05

What researchers measure

Primary outcomes

  1. adverse events

    Such adverse events include (but are not limited to) infection, repeated removal of implanted bio-scaffold, the humoral immunological responses.

    Time frame: 1 year after surgery

Secondary outcomes

  1. Cosmetic outcome

    excellent (size and shape of reconstructed breast are identical to the original breast); good (deformity of the reconstructed breast involved less than 1/4 of the original breast; fair (deformity of the reconstructed breast involves less than 1/4-1/2 of the original breast); and poor (breast deformity involves more than 1/2 of the original breast).

    Time frame: 6 months after surgery

  2. Satisfaction of patients

    The satisfaction of patients was investigated by self-made questionnaire

    Time frame: 6 months after surgery

  3. Recurrence rate

    5 year recurrence was observed

    Time frame: 5 year after surgery

  4. 5-Year disease free survival

    5 year survival was observed

    Time frame: 5 year after surgery

06

Study locations

1 site
  • Xijing hospital
    Xi'an, Shaanxi 710032, China
07

References and documents

Publications

  • The utility of 3D printing for surgical planning and patient-specific implant design for complex spinal pathologies: case report. J Neurosurg Spine. 2017 Apr;26(4):513-518. doi: 10.3171/2016.9.SPINE16371. Epub 2017 Jan 20. PubMed 28106524 ↗
  • Chia HN, Wu BM. Recent advances in 3D printing of biomaterials. J Biol Eng. 2015 Mar 1;9:4. doi: 10.1186/s13036-015-0001-4. eCollection 2015. PubMed 25866560 ↗
  • Ibrahim AM, Jose RR, Rabie AN, Gerstle TL, Lee BT, Lin SJ. Three-dimensional Printing in Developing Countries. Plast Reconstr Surg Glob Open. 2015 Aug 10;3(7):e443. doi: 10.1097/GOX.0000000000000298. eCollection 2015 Jul. PubMed 26301132 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03348293
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Nov 20, 2017
Start date
Jul 30, 2018
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Aug 3, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion